Literature DB >> 27553087

Outcome of acute severe ulcerative colitis in patients previously exposed to immunosuppressive therapy.

Simona Deiana1, Siro Bagnoli1, Natalia Manetti1, Saverio Caini2, Martina Giannotta3, Stefano Scaringi4, Vito Annese5.   

Abstract

BACKGROUND AND AIM: We aimed to evaluate the outcome of patients with acute severe ulcerative colitis previously exposed to immunosuppressive (IMS) therapy.
METHODS: We retrospectively collected data from 86 consecutive patients from 2008. Early outcome was evaluated as response to steroids, rescue therapy, and colectomy rate, whereas colectomy free-survival was determined along the follow-up.
RESULTS: The overall response rates to steroids and rescue therapy was 33.7% and 90.5%, respectively, while early colectomy rate was 22.1%. Patients previously treated with IMS (n=47) showed a trend towards lower response to steroids (25.5% vs 43.6%; p=0.10), and a high-risk of early colectomy (29.8% vs 12.8%; p=0.07), but a similar response to rescue therapy (87.5% vs 94.4%, p=0.62) when compared with IMS-naïve patients (n=39). The overall cumulative probability to avoid the surgery was 67.5% and 56.6% at 12 and 60 months, respectively, regardless of previous exposure to IMS (p=0.30). At multivariate analysis the risk of early colectomy was increased by previous IMS (OR 5.16, p=0.017), anaemia (OR 4.26, p=0.02), and diagnosis above 40 years (OR 5.31, p=0.011).
CONCLUSIONS: Patients previously treated with IMS showed a non-significant trend towards a worse response with steroid therapy, a satisfactory response rate to rescue therapy, and a similar probability of avoiding colectomy during the follow-up vs IMS-naive patients.
Copyright © 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute severe ulcerative colitis; Colectomy rate; Cyclosporine; Immunosuppressive drugs; Infliximab

Mesh:

Substances:

Year:  2016        PMID: 27553087     DOI: 10.1016/j.dld.2016.07.021

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  3 in total

1.  Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study.

Authors:  Marco Le Grazie; Siro Bagnoli; Gabriele Dragoni; Saverio Caini; Vito Annese; Tommaso Innocenti; Simona Deiana; Natalia Manetti; Stefano Milani; Andrea Galli; Monica Milla
Journal:  Ann Gastroenterol       Date:  2021-01-27

2.  Increased Gene Copy Number of DEFA1A3 Is Associated With the Severity of Ulcerative Colitis.

Authors:  Shuji Kanmura; Yuko Morinaga; Akihito Tanaka; Yuga Komaki; Hiromichi Iwaya; Kotaro Kumagai; Seiichi Mawatari; Fumisato Sasaki; Shiroh Tanoue; Shinichi Hashimoto; Yoichi Sameshima; Yohei Ono; Hidehisa Ohi; Akio Ido
Journal:  Clin Transl Gastroenterol       Date:  2021-04-06       Impact factor: 4.396

3.  Left-sided colitis and extensive colitis have similar colectomy rates after index episode of acute severe colitis: A long-term follow-up study.

Authors:  Saransh Jain; Saurabh Kedia; Sawan Bopanna; Dawesh P Yadav; Sandeep Goyal; Peush Sahni; Nihar R Dash; Sujoy Pal; Govind Makharia; Vineet Ahuja
Journal:  JGH Open       Date:  2017-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.